Preferred Label : Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310;
NCIt synonyms : Anti-EphA2 Docetaxel-based Nanoliposome MM-310; EphA2-targeted Docetaxel Nanoliposome MM-310; Anti-EphA2 Antibody-targeted Nanoliposome MM-310;
NCIt definition : A formulation containing nanoparticles composed of liposomes that are conjugated to
scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2)
and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation
taxane analog, with potential antineoplastic activity. Upon intravenous administration
of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2
moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation
of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site
due to the unique characteristics of the tumor vasculature. In turn, docetaxel is
taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin,
thereby stabilizing microtubules and inhibiting microtubule disassembly. This results
in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2,
a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved
in mammalian development, is overexpressed by a variety of cancer cell types and plays
an important role in tumor growth; its expression is associated with poor prognosis.
Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced
and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's
efficacy while lowering its systemic toxicity.;
Molecule name : MM 310; MM-310;
NCI Metathesaurus CUI : CL524774;
Origin ID : C136981;
UMLS CUI : C4527153;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
